Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence of COVID-19 Pneumonia and Clinical Characteristics in Hemodialysis Patients During the SARS-CoV-2 Omicron Pandemic.

Nephron·2026

Same author

Incremental peritoneal dialysis preserves residual renal function in diabetic end-stage kidney disease.

Renal failure·2026

Same author

Efficacy and safety of six immunoadsorption treatments for severe lupus nephritis: a Bayesian network meta-analysis and systematic review.

Frontiers in immunology·2026

Same author

Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women.

NPJ breast cancer·2026

Same author

Recent Advances in Organocatalytic Kinetic Resolution for the Synthesis of Axially Chiral Compounds.

Molecules (Basel, Switzerland)·2026

Same author

The Heavy Toll of Lifeline: An Analysis of the Multidimensional Experience and Interaction Mechanisms of Establishing Arteriovenous Fistula in Patients Receiving Haemodialysis.

Journal of renal care·2026

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

mTOR Inhibitors at a Glance.

Yin Zheng¹, Yu Jiang²

¹Medical Health Care Center, Hainan Provincial People's Hospital, Haikou, China.

Molecular and Cellular Pharmacology

|May 3, 2016

Summary

Mechanistic target of rapamycin (mTOR) is a key protein kinase regulating cell growth. This commentary summarizes mTOR inhibitors developed as potential cancer therapies.

Keywords:

Akt Kinase inhibitors Phosphatidylinositol-3-kinase Rapamycin mTOR

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Mar 21, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase regulating cell growth and proliferation.
mTOR is a validated therapeutic target for cancers driven by uncontrolled cell proliferation.
The immunosuppressive drug rapamycin was the first identified mTOR inhibitor.

Purpose of the Study:

To provide a concise summary of mTOR inhibitors.
To highlight the development and clinical trial status of mTOR inhibitors for cancer treatment.

Main Methods:

Literature review of mTOR inhibitors.
Analysis of clinical trial data for mTOR inhibitors.

Main Results:

Numerous mTOR inhibitors have been developed over the past decade.
Many mTOR inhibitors are currently undergoing clinical trials for various cancers.

Conclusions:

mTOR inhibitors represent a promising class of targeted cancer therapies.
Further research and clinical evaluation are ongoing for mTOR-targeted treatments.